1. Technical Field
The present invention relates to a system and method for detecting and analyzing microbial activity.
2. Description of Related Art
The ASM (American Society for Microbiology) recommends that microbial samples be tested within 2 hours of sampling to maintain representative characteristics of the sample. It is the current practice in the field of urinary tract infection (UTI) analysis to analyze samples after 12-24 hours of sample storage. While precautions are taken to minimize microbial specie balance and concentration levels changes, industry studies demonstrate that sample representativeness is significantly compromised. Hence, the number of false positives and false negatives due to contamination and time are significant in the over prescribing of treatment drugs, unneeded hospital stays and general time insensitive test results for medical staff (e.g., MDs).
According to an embodiment of the present disclosure, a method for testing a microbial population including a negative screen includes inoculating a plurality of test ampoules with respective samples, performing a first light transmittance test on the test ampoules, recording first test data, performing a second light transmittance test on the test ampoules, recording second test data, detecting negative samples based on the first test data and the second test data, and reporting negative samples based on the first test data and the second test data.
According to an embodiment of the present disclosure, a method for testing a microbial population including a false positive screen includes inoculating a plurality of test ampoules with respective samples, performing a first light transmittance test on the test ampoules, recording first test data, performing a second light transmittance test on the test ampoules, recording second test data, detecting samples positive for the presence of the microbial population based on the first test data and the second test data, and reporting the samples positive for the presence of the microbial population based on the first test data and the second test data.
Preferred embodiments of the present disclosure will be described below in more detail, with reference to the accompanying drawings:
According to an embodiment of the present disclosure, a liquid sample can be analyzed for the presence and activity of a biologic component by determining the transmittance of light through the sample, wherein the transmittance visible light is indicative of respiration and infrared light is indicative of a chemical reaction (e.g., reduction due to a TTC indicator). Multiple tests can be performed on the same sample at different times to determine growth characteristics of the sample. Further, according to an embodiment of the present disclosure, false negative results and false positive results may be identified for individual samples. In a first test or read determinations (e.g., positive/negative for the presence of bacteria) are made based on predetermined histograms based on physical properties of the sample for visible and IR, log/lag phase determinations in time to concentrations analysis, and microbe identification. In a subsequent test or read log/lag phases determinations may be confirmed, microbes identified, and false positive and negative samples (as identified in the first test) can be identified.
A spectrophotometer is used to read and record light transmission through an aqueous sample, where measures are recorded in a test record. The sample is taken and wavelengths are selected for first read analysis, these wavelengths for testing are available through the spectrophotometer having different light sources. A determination of potentially positive samples may be made using the first read analysis. The samples, e.g., potential positive samples, may be incubated and a second read is performed for each wavelength of the first read. A change in light transmission through the sample over time is determined. For example, if an increase in absorbance and/or a decrease in transmittance in a visible wavelength and an IR wavelength is determined, than the sample is confirmed to be positive. According to an embodiment of the present disclosure, negative samples may be determined during the first read analysis and discarded. Further, by comparing the curves for light transmission over time with known curves for a given species, a species of the sample can be determined and or the susceptibility to various anti microbial agents can be determined.
For example, a human urine analysis for 106 microbial concentration using 580 nm and 800 nm at 2 hours of incubation is considered positive if the 580 nm drops 20% T (transmission rate) or more and the 800 nm reading drops 10% T or more. With the predetermined spectral change information, the sample may be withdrawn from incubation and read spectrophotometrically a second time. The spectral output change is then compared to the predetermined values for change to be classified positive or negative. If a change in light transmittance satisfies a known value for a positive sample, the sample is considered positive and in the log phase of growth at time of sampling. If a change in light transmittance satisfies a known value of a negative sample, the sample is considered negative for the light wavelengths being tested and any bacteria present are in lag phase.
In this context, a negative screen system may be implemented which uses a collection of data points to reduce a number of potential false positives and to improve the use of scarce bio-laboratory resources.
According to an embodiment of the present disclosure, the act of inoculating a test ampoule is a start of the test. In conventional methods a test is not begun until a growth plate is streaked in a laboratory environment, leading to aging of the sample—samples are typically considered not to be representative if they are older than about 2-3 hours without refrigeration to stop bacterial growth.
The test ampoule is a controlled testing environment. Sample representativeness is ensured through the inoculation and simultaneous test start. The first read can therefore be done at the time of inoculation (e.g., within about 2-3 hours of inoculation) or later if the sample is refrigerated. By ensuring sample representativeness the probability of false positive and false negative results can be reduced. According to an exemplary embodiment, in the case of urine testing (UTI), by substantially eliminated false results, doctors can more accurately prescribe medication and avoid using medication for well patients.
According to an embodiment of the present disclosure, a test system can be expanded to include a satellite system in communication with a central system, without loss of bio-expertise or control. A single test system may be used to perform the methods described herein.
A satellite system may be used to first capture midstream urine sample microbiology characteristics at the time of inoculation (e.g., within about 30 minutes of inoculation). Testing of old urine samples, e.g., 8-20 hours, is a reason for inflated positive UTI reporting rates and a group of false negatives called “Mixed Contaminants” in prior systems.
According to an embodiment of the present disclosure, test inoculation for urine UTI culturing may be performed in the field (e.g., at the test site). The satellite system includes a computer system including a database and code for the elimination of potential false positives.
The satellite system may be based on the configuration and protocol as described below. At the satellite collection laboratory, a test system may be installed including the following components: reader, single read non-incubating reader or multi reading with auto incubation (e.g., spectrophotometer); database (including known characteristics of different microbes) and computer system, which may include video conferencing capabilities; bar code reader for use with labeled test ampoules and software for tracking the ampoules over multiple tests; and test ampoules. The test ampoules may be a sealed container having a negative pressure therein for drawing a predetermined volume of liquid into the ampoule. The test ampoules may further include a reagent dosed into the sealed container.
For small samples (e.g., pediatric samples), a sample may be diluted, e.g., up to about 1:9, to make adequate sample available throughout the process. Computer software can auto adjust all test criteria for first and second read and incubation time.
At the central laboratory, a master test system can be installed including the following components: a reader, single read and non-incubating or multi read auto-incubating; database and computer system with video conference capability; bar code reader; and test ampoules.
At the central laboratory, laboratory test data may be collected, up-loaded and reviewed.
For the culture-probable samples are sent to the central lab at block 207 together with a test data file at block 208. The test data file can be opened (at block 209) and reviewed (at block 210). Block 211 shows that the ampoule was previously inoculated (e.g., at block 201) and the negative screen protocol 2 is begun at block 212. At block 212 the sample is tested to determine whether a change has occurred during transportation (e.g., was the sample refrigerated during transportation to substantially prevent growth). If, at block 213, changes in the visible and infrared transmittance of the sample are outside predetermined ranges, or a combination thereof, then the test is concluded for that sample; note that the first test (e.g., block 201) is still valid. The predetermined range can be determined through experiment. The comparison at block 213 may result in a negative result or result in further incubation at block 214 for samples which have been verified to be within the predetermined range of the first read, followed by a second read at block 215 to confirm the presence of a culture at block 216. The central lab results of block 215 are compared to the first read at block 202. The computer aided analyst may then make speciation determinations for microbial species based on prior knowledge of test results for different species.
This laboratory protocol would have the added advantage of the first test-read data from the satellite collection lab at block 202. The use of the first read on the fresh sample versus a central lab first-read assists in false positive detection and the currently undetectable sample change (in conventional methods, e.g., streaking plates at a central lab) during the sample custody/transportation period.
The central laboratory review of test data from the satellite collection lab would be needed before reporting negatives. Any doubtful results would be confirmable or reviewed revisable by video conference and/or a re-reading of the retained samples.
For those samples deemed positive by the master system at the central laboratory, the contents of fresh positive test ampoules would be used to inoculate the speciation culture plate with log phase microbes. An ampoule neck-cutting process (breaking open the ampoule) can be applied to the test ampoule to allow for the speciation process.
The expanded satellite test system may exhibit one or more of the following:
As shown in
It should be noted that thresholds (e.g., see
Referring to
The extended pre-incubation period also allows the confirming Read 2 to be made sooner as positives have less distance to vector to demonstrate positivity.
The period of pre-incubation can be varied according to the age of the same; for example, for a sample less than about 3 hours old, a pre-incubation of about 10-15 minutes can be used, for a sample about 4-12 hours old, a pre-incubation of 1 hours can be used, for a sample older than about 12 hours, a pre-incubation of about 1.5 hours can be used.
Referring to the negative screen,
According to an embodiment of the present disclosure, a grid map is created that segments visible and IR readings into sections, for example, 4 quadrants (QUAD 1-4), and a determination of positive/negative may be made according to an observations plot. For example, a particular value for each of visible and IR is optimized for the determination. For example,
Referring to
It is to be understood that the present invention may be implemented in various forms of hardware, software, firmware, special purpose processors, or a combination thereof. In one embodiment, the present invention may be implemented in software as an application program tangibly embodied on a program storage device. The application program may be uploaded to, and executed by, a machine comprising any suitable architecture.
Referring to
The computer platform 701 also includes an operating system and micro instruction code. The various processes and functions described herein may either be part of the micro instruction code, or part of the application program (or a combination thereof) which is executed via the operating system. In addition, various other peripheral devices may be connected to the computer platform such as an additional data storage device and a printing device.
It is to be further understood that, because some of the constituent system components and methods depicted in the accompanying figures may be implemented in software, the actual connections between the system components (or the processes) may differ depending upon the manner in which the present disclosure is programmed. Given the teachings of the present disclosure provided herein, one of ordinary skill in the related art will be able to contemplate these and similar implementations or configurations of the present disclosure.
Having described embodiments for a system and method for detecting and analyzing microbial activity, it is noted that modifications and variations can be made by persons skilled in the art in light of the above teachings. It is therefore to be understood that changes may be made in the particular embodiments of the invention disclosed which are within the scope and spirit of the disclosure.
This application claims priority to U.S. Provisional Application Ser. No. 60/957,028, filed on Aug. 21, 2007, which is herein incorporated by reference in its entirety.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US08/73885 | 8/21/2008 | WO | 00 | 2/22/2010 |
Number | Date | Country | |
---|---|---|---|
60957028 | Aug 2007 | US |